Concord Biotech (BOM:543960) Interest Expense: ₹-3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543960 Concord Biotech Ltd BOM:543960
90 GF Score
Price ₹1,513.40
GF Value ₹1,672.88
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Concord Biotech Interest Expense?

Concord Biotech BOM:543960 +4.65% 90 Interest Expense is ₹-3 Mil as of Jun. 2026. GuruFocus rates BOM:543960 with a GF Score™ of 90/100 and a GF Value™ of ₹1,672.88 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Concord Biotech's interest expense for the three months ended in Jun. 2026 was ₹ -0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Concord Biotech's Operating Income for the three months ended in Jun. 2026 was ₹ 643 Mil. Concord Biotech's Interest Expense for the three months ended in Jun. 2026 was ₹ -0 Mil. Concord Biotech's Interest Coverage for the quarter that ended in Jun. 2026 was 1,765.83. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Concord Biotech  (BOM:543960) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Concord Biotech's Interest Expense for the three months ended in Jun. 2026 was ₹-0 Mil. Its Operating Income for the three months ended in Jun. 2026 was ₹643 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ₹0 Mil.

Concord Biotech's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*642.763/-0.364
=1,765.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Concord Biotech Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Concord Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Concord Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech Interest Expense Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial -54.84 -45.10 -25.52 -5.29 -2.82

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -0.59 -0.82 -0.84 -0.36
BOM:543960
90GF Score
Concord Biotech Ltd BOM:543960
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-3 Mil mean?
Concord Biotech (BOM:543960) has a Interest Expense of ₹-3 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Concord Biotech and its competitors.
Is Concord Biotech's Interest Expense too high?
Concord Biotech's current Interest Expense is ₹-3 Mil. Overall, Concord Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Interest Expense compare to VRTX and REGN?
Concord Biotech's Interest Expense of ₹-3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Concord Biotech and its competitors. Concord Biotech's current Interest Expense is ₹-3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,672.88, compared to a current price of ₹1,513.40 — trading 9.5% below its estimated fair value. The current Interest Expense is ₹-3 Mil. Concord Biotech's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Interest Expense is ₹-3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Biotech (BOM:543960) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued. The current stock price of ₹1,513.40 is trading 9.5% below its estimated GF Value™ of ₹1,672.88. GuruFocus considers Concord Biotech to be Modestly Undervalued.

Key valuation signals for BOM:543960:

  • Interest Expense: ₹-3 Mil
  • GF Value™: ₹1,672.88 vs. price of ₹1,513.40 (9.5% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Biotech Business Description

Other Exchanges CONCORDBIO:India
Address Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
90GF Score

Get the complete analysis for BOM:543960

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,513.40
Price
₹1,672.88
GF Value